Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

In vivo CRISPR Screening Identifying Therapeutic Target to Sensitize Anti-PD-1 Immunotherapy in Non-small Cell Lung Cancer

ABSTRACT: Although immunotherapy has achieved great success in lung adenocarcinoma (LUAD), only a subset of patients exhibit a favorable response. Leveraging LUAD mono-immunotherapy RNA-sequencing data, we identified differentially expressed genes associated with immunotherapy efficacy by comparing immunotherapy-sensitive and immunotherapy-insensitive patients. These genes were utilized to construct a customized sgRNA library. Two in vivo CRISPR screening models including Lewis lung carcinoma (LLC) and KrasG12D/Trp53-/-(KP) models were developed to identify novel targets regulating immunotherapy efficacy. After transducing the customized sgRNA library, LLC/KP-Cas9 library cells were injected into mice divided into three groups: Rag1-/- C57BL/6 immunodeficient mice treated with IgG antibody, and wild type C57BL/6 immunocompetent mice treated with anti-PD-1 antibody or isotype IgG antibody. Tumors were harvested after 2-4 weeks of treatment, genomic DNA was isolated, and next-generation sequencing (NGS) was performed to analyze sgRNA distribution. By comparing the sgRNAs detected in wild-type C57BL/6 immunocompetent mice treated with anti-PD-1 antibody versus isotype IgG, potential targets that regulating immunotherapy efficacy were identified.

ORGANISM(S): Mus musculus

PROVIDER: GSE301822 | GEO | 2025/07/09

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

In vitro and in vivo epigenome-wide CRISPR screens in mouse KrasG12D/P53-/- (KP) lung adenocarcinoma model

Project description:To systematically study the functions of epigenetic genes in controlling tumor progression and regulating anti-tumor immunity, we performed a series of in vitro and in vivo epigenome-wide CRISPR screens in mouse KP lung adenocarcinoma model. We constructed an epigenetic-focused sgRNA library, established KP-Cas9-library pools, and then performed in vitro and in vivo CRISPR screens. For in vitro screens, we compared the cell pools harvested at week 4 with the cells pools harvested at week 2 to check the functions of epigenetic genes in tumor cell proliferation. For in vivo screens, we compared the IgG treated tumors in Rag1-/- mice or WT mice with the input cell pool to check the functions of epigenetic genes in tumor growth; we compared the IgG treated tumors in WT mice with the IgG treated tumors in Rag1-/- mice to check the functions of epigenetic genes in regulating anti-tumor immunity; we compared the anti-PD-1 treated tumors in WT mice with IgG treated tumors in WT mice to check the functions of epigenetic genes in modulating sensitivity to anti-PD-1 treatment.

2019-11-26 | GSE127232 | GEO

Genome-wide identification of RNA polymerase, RpoD, and RpoS binding sites in Klebsiella pneumoniae MGH 78578

Project description:Genome-wide identification of RNA polymerase (RNAP) binding sites were performed in Klebsiella pneumoniae MGH 78578 (KP). Anti-RNAP is used to capture the RNAP in KP. ChIP-chip was performed on tiling array specifically made for KP. Comparison ChIP by anti-RNAP antibody vs ChIP by normal mouse IgG (control, mock IP)

2012-12-31 | E-GEOD-35927 | biostudies-arrayexpress

RNA-seq to compare gene expression profiles between Asf1a WT and Asf1a KO cells

Project description:KrasG12D/P53-/-(KP)-Cas9 single clone was transfected with ctrl vector, ctrl sgRNA-1, ctrl-sgRNA-2 or ctrl-sgRNA-3 and then selected by using 5ug/ml Blasticidin, to get the 4 ctrl lines; KP-Cas9 single clone was transfected with Asf1a sgRNA-1, sgRNA-2, sgRNA-3 and new sgRNA-1 and then selected by using 5ug/ml Blasticidin, and then picked up single clones with Asf1a KO. For each Asf1a sgRNA, we selected one clone for RNA seq, so totally we have 4 Asf1a KO clones for RNA seq.

2019-11-26 | GSE127205 | GEO

In vivo epigenetic CRISPR screen identifies Asf1a as an immunotherapeutic target in Kras-mutant lung adenocarcinoma

Project description:Despite substantial progress in lung cancer immunotherapy, the overall response rate in KRAS-mutant lung adenocarcinoma (ADC) patients remains low. Combining standard immunotherapy with adjuvant approaches that enhance adaptive immune responsesâ€”such as epigenetic modulation of anti-tumor immunityâ€”is therefore an attractive strategy. To identify epigenetic regulators of tumor immunity, we constructed an epigenetic-focused sgRNA library, and performed an in vivo CRISPR screen in KrasG12D/P53-/- (KP) lung ADC model. Our data showed that loss of the histone chaperone Asf1a in tumor cells sensitizes tumors to anti-PD-1 treatment. Mechanistic studies revealed that tumor cell intrinsic Asf1a deficiency induced immunogenic macrophage differentiation in the tumor microenvironment by upregulating GM-CSF expression and potentiated T cell activation in combination with anti-PD-1. Our results provide a rationale for a novel combination therapy consisting of Asf1a inhibition and anti-PD-1 immunotherapy.

2019-11-26 | GSE138571 | GEO

A customized synthetic gene circuit selectively engages an immune-related transcriptional program in p53-negative LLC cells

Project description:Purpose: Cancer immunotherapy has shown promising results in both mouse models and clinical trials. However, to specifically reprogram the immune microenvironment of advanced tumor lesions remains a huge challenge. Therefore, we assembled a synthetic gene circuit aimed at specifically targeting p53-negative LLC cells, but not their p53+ derivatives, for immune activation. Methods: Firstly, we established an LLC-derived knock-in line (p53+), where the WT p53 coding region was re-introduced into the endogenous locus to rescue the bi-allelic point mutations (a nonsense mutation at E32, and a R334P mutation) in the parental LLC cells. Next, both the parental LLC cells and p53+ LLC cells were introduced with the AND-NOT gene circuits which contains the tumor-specific survivin promoter-driven dCas9 (Psuv-dCas9), U6 promoter-driven Ifng-activating sgRNA (or control sgRNA), and p53-responsive promoter PM2-driven AcrIIA4max. 48 hours after transfection, the total RNA was isolated and subjected to RNAseq services. Results: The p53+ LLC cell showed differences of hundreds of genes compared with the parental LLC cells. This group of genes contain a number of classical p53 targets. Notably, the logic circuit drove selective induction of a different gene set in the parental, but not the p53+ cells. Importantly, the vast majority of the circuit-induced genes are known downstream targets of IFN, confirming the specificity of a CRISPRa-driven transcriptional rewiring. Conclusion: Overall, this dataset provides evidence that the AND-NOT gene circuit selectively targets p53-negative LLC cells, but not their p53+ derivatives, and subsequently programs a highly specific immune-rewiring output.

2022-02-23 | GSE179814 | GEO

Tumor-specific mechanism of Treg enrichment mediated by the integrin avb8

Project description:Subcutaneous tumors from mock transfected LLC or b8 transfected LLC were established on flanks of C57B/6 FoxP3-Ires GFP mice. Mice were treated with isotype control antibodies or anti-b8 and Tregs (CD4+ GFP+) were sorted, pooled and total RNA isolated for RNAseq.

2021-02-23 | GSE158031 | GEO

Tead1 regulation of β-cells II

Project description:Purpose: The goal of this study is to determine the regulatory role of Tead1 in β-cells by analyzing the Tead1 cistrome and open chromatin in β-cells Methods: Isolated islets from WT C57bl6 mice of 12 weeks of age were flash frozen. For Chip-seq they were fixed with formaldehyde and then after sonication, IP was performed with Anti-Tead1 antibody or the IgG isotype control. For ATAC-seq 100,000 of the frozen nuclei were tagmented. After DNA extraction, library construction, sequencing was performed using Illumina Hi seq2500. Conclusions: Our study represents the first detailed analysis of the Tead1 cistrome in beta cells.

2022-12-14 | GSE157513 | GEO

DDR1 plays a distinctive role in mammary tumour growth

Project description:Purpose: The goals of this study are to compare mammary tumor transcriptome profiling with or without DDR1 in immunocompetent mice in an unbiased way. Methods: In vitro samples: DDR1 WT or KO in vitro cultured E0771 cells were sequenced. Rag1-/- samples: DDR1 WT or KO E0771 cells were injected in Rag1-/- mice, and tumors were harvested and sequenced. C57BL/6 samples: DDR1 WT or KO E0771 cells were firstly inoculated into Rag1-/- mice. When tumor volume reached approximately 200~300 mm3 (usually 20 days after inoculation), 60 mg of tumor organoid were transplanted to WT C57BL/6 mice. Tumor samples were collected on day 4 after transplantation for RNA-seq. Antibody treatment samples: DDR1 KO E0771 cells were reconstituted with human DDR1, then injected into C57BL/6 mice. Isotype control IgG or anti-hDDR1 ECD antibody treatment (10mg/kg intrutumural) started when tumor volume reached approximately 100 mm3. Tumor samples were collected on day 6 after treatment for RNA-seq. Results: Approximately 50 million sequence reads were obtained per sample and identified more than 20,000 transcript isoforms. Conclusions: The RNA-seq results represents the detailed analysis of DDR1 WT/KO mammary tumor transcriptomes in immunocompetent mice C57BL/6.

2021-09-07 | GSE139239 | GEO

Transcriptional re-programming of primary human macrophages by IRF-3 and IRF-7

Project description:This SuperSeries is composed of the following subset Series: GSE11926: Transcriptional profiles of Ad-F3 and Ad-F7 transduced macrophages. GSE12002: Transcriptional profiles of Ad-F7 transduced macrophages in the presence of neutralizing antibody for the type I interferon receptor (IFNAR2) or control isotype (IgG). Refer to individual Series

2008-11-29 | E-GEOD-12120 | biostudies-arrayexpress

Post-ICB treatment PDAC infiltrating T cells TCR profile

Project description:For the subcutaneous model, 5x105 KPC-Luc cells were injected subcutaneously near the right flank of female C57BL/6 mice. 6-7 days after tumor implantation mice were randomized into 4 treatment groups and treatedwith VIP-R antagonist and/or anti-PD-1. While scram+IgG control mice received scrambled peptide and isotype IgG, the VIP-R antagonist, anti-PD-1 and VIP-R antagonist and anti-PD-1 groups received VIP-R antagonist and IgG; scrambled peptide and anti-PD-1; and VIP-R antagonist and anti-PD-1, respectively. The treatment regimen involved administering 10μg of scrambled or VIP-R antagonist: ANT008, subcutaneously every day and 200μg of IgG or anti-PD-1 intraperitoneally once every three days, for a total of 10 days.

2022-09-19 | GSE213482 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data